577 related articles for article (PubMed ID: 12566656)
21. Protecting the peritoneal membrane in dialyzed patients.
Grzegorzewska AE
Adv Med Sci; 2006; 51():191-6. PubMed ID: 17357307
[TBL] [Abstract][Full Text] [Related]
22. The importance of biocompatibility in peritoneal dialysis solutions.
Passlick-Deetjen J
Perit Dial Int; 1993; 13 Suppl 2():S101-4. PubMed ID: 8399540
[No Abstract] [Full Text] [Related]
23. Advanced glycation end-products and peritoneal sclerosis.
Nakamura S; Niwa T
Semin Nephrol; 2004 Sep; 24(5):502-5. PubMed ID: 15490420
[TBL] [Abstract][Full Text] [Related]
24. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
[TBL] [Abstract][Full Text] [Related]
25. Acute inflammation in peritoneal dialysis: experimental studies in rats. Characterization of regulatory mechanisms.
Bazargani F
Swed Dent J Suppl; 2005; (171):1-57, i. PubMed ID: 15847249
[TBL] [Abstract][Full Text] [Related]
26. Solutions for APD: special considerations.
Passlick-Deetjen J; Schaub TP; Schilling H
Semin Dial; 2002; 15(6):407-13. PubMed ID: 12437535
[TBL] [Abstract][Full Text] [Related]
27. [The role of cytokines in peritoneal dialysis].
Opatrná S; Topolcan O; Opatrný K
Vnitr Lek; 2000 Nov; 46(11):794-800. PubMed ID: 15637896
[TBL] [Abstract][Full Text] [Related]
28. What can we do to preserve the peritoneum?
Krediet RT; Zweers MM; van Westrhenen R; Ho-dac-Pannekeet MM; Struijk DG
Perit Dial Int; 2003 Dec; 23 Suppl 2():S14-9. PubMed ID: 17986535
[TBL] [Abstract][Full Text] [Related]
29. Inflammation in peritoneal dialysis.
Lai KN; Leung JC
Nephron Clin Pract; 2010; 116(1):c11-8. PubMed ID: 20460934
[TBL] [Abstract][Full Text] [Related]
30. Differences in peritoneal response after exposure to low-GDP bicarbonate/lactate-buffered dialysis solution compared to conventional dialysis solution in a uremic mouse model.
Vila Cuenca M; Keuning ED; Talhout W; Paauw NJ; van Ittersum FJ; Ter Wee PM; Beelen RHJ; Vervloet MG; Ferrantelli E
Int Urol Nephrol; 2018 Jun; 50(6):1151-1161. PubMed ID: 29728994
[TBL] [Abstract][Full Text] [Related]
31. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor.
Aroeira LS; Aguilera A; Selgas R; Ramírez-Huesca M; Pérez-Lozano ML; Cirugeda A; Bajo MA; del Peso G; Sánchez-Tomero JA; Jiménez-Heffernan JA; López-Cabrera M
Am J Kidney Dis; 2005 Nov; 46(5):938-48. PubMed ID: 16253736
[TBL] [Abstract][Full Text] [Related]
32. Improved biocompatibility of bicarbonate/lactate-buffered PDF is not related to pH.
Zareie M; Keuning ED; ter Wee PM; Schalkwijk CG; Beelen RH; van den Born J
Nephrol Dial Transplant; 2006 Jan; 21(1):208-16. PubMed ID: 16263741
[TBL] [Abstract][Full Text] [Related]
33. Peritoneal fibrosis intervention.
Kaneko K; Hamada C; Tomino Y
Perit Dial Int; 2007 Jun; 27 Suppl 2():S82-6. PubMed ID: 17556336
[TBL] [Abstract][Full Text] [Related]
34. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients.
Zhou Q; Bajo MA; Del Peso G; Yu X; Selgas R
Kidney Int; 2016 Sep; 90(3):515-24. PubMed ID: 27282936
[TBL] [Abstract][Full Text] [Related]
35. PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage.
Sandoval P; Loureiro J; González-Mateo G; Pérez-Lozano ML; Maldonado-Rodríguez A; Sánchez-Tomero JA; Mendoza L; Santamaría B; Ortiz A; Ruíz-Ortega M; Selgas R; Martín P; Sánchez-Madrid F; Aguilera A; López-Cabrera M
Lab Invest; 2010 Oct; 90(10):1517-32. PubMed ID: 20531289
[TBL] [Abstract][Full Text] [Related]
36. Evidence for Biocompatible Peritoneal Dialysis Solutions.
Nataatmadja M; Cho Y; Johnson DW
Contrib Nephrol; 2017; 189():91-101. PubMed ID: 27951555
[TBL] [Abstract][Full Text] [Related]
37. Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.
Mortier S; Faict D; Schalkwijk CG; Lameire NH; De Vriese AS
Kidney Int; 2004 Sep; 66(3):1257-65. PubMed ID: 15327425
[TBL] [Abstract][Full Text] [Related]
38. Unfavorable Effects of Peritoneal Dialysis Solutions on the Peritoneal Membrane: The Role of Oxidative Stress.
Roumeliotis S; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
Biomolecules; 2020 May; 10(5):. PubMed ID: 32423139
[TBL] [Abstract][Full Text] [Related]
39. Neutral pH and low-glucose degradation product dialysis fluids induce major early alterations of the peritoneal membrane in children on peritoneal dialysis.
Schaefer B; Bartosova M; Macher-Goeppinger S; Sallay P; Vörös P; Ranchin B; Vondrak K; Ariceta G; Zaloszyc A; Bayazit AK; Querfeld U; Cerkauskiene R; Testa S; Taylan C; VandeWalle J; Yap Y; Krmar RT; Büscher R; Mühlig AK; Drozdz D; Caliskan S; Lasitschka F; Fathallah-Shaykh S; Verrina E; Klaus G; Arbeiter K; Bhayadia R; Melk A; Romero P; Warady BA; Schaefer F; Ujszaszi A; Schmitt CP
Kidney Int; 2018 Aug; 94(2):419-429. PubMed ID: 29776755
[TBL] [Abstract][Full Text] [Related]
40. Effect of the dialysis fluid buffer on peritoneal membrane function in children.
Schmitt CP; Nau B; Gemulla G; Bonzel KE; Hölttä T; Testa S; Fischbach M; John U; Kemper MJ; Sander A; Arbeiter K; Schaefer F
Clin J Am Soc Nephrol; 2013 Jan; 8(1):108-15. PubMed ID: 23124784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
